You just read:

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer

News provided by

Astellas Pharma Inc.

Dec 02, 2019, 08:00 ET